The Relationship Between Serum Lipoprotein (a) Levels and Ischemic Stroke Risk: A Cohort Study in the Chinese Population
- 303 Downloads
The role of atherosclerosis in ischemic stroke has been intensively investigated in recent years, and lipoprotein (a) [Lp(a)] is found to have roles during the process. The aim of this study was to investigate the relationship between acute ischemic stroke (AIS) and serum Lp(a) levels in the Chinese population. All consecutive patients with first-ever acute ischemic stroke during 2011–2012 were recruited to participate in the study. Serum Lp(a) levels and routine tests were examined in both groups. The National Institutes of Health Stroke Scale (NIHSS) score was assessed on admission blinded to Lp(a) levels. In this study, 181 patients with acute ischemic stroke were included. There was a significant difference in median serum Lp(a) levels between acute ischemic stroke patients and control cases (328 [IQR, 173–554] vs. 145 [IQR, 66–254] mg/L, respectively; P = 0.000). Lp(a) levels increased with increasing severity of stroke as defined by the NIHSS score (P = 0.000). For the entire group, when adjusting for other possible risk factors, an elevated Lp(a) level was an independent risk factor for stroke, and a serum Lp(a) level ≥300 mg/L was associated with a 2.23-fold increase in AIS (P = 0.015). In addition, this association was stronger in male than in female patients. High Lp(a) levels are significantly related to stroke, independent from other traditional and emerging risk factors, suggesting that they may play a role in its pathogenesis. It should be considered as a routine risk factor for stroke in the Chinese population.
KEY WORDSacute ischemic stroke lipoprotein (a) Chinese risk serum biomarker
We express our gratitude to all the patients who participated in this study, thereby making this work possible. The content has not been published or submitted for publication elsewhere.
- 5.Nordestgaard, B.G., M.J. Chapman, K. Ray, J. Borén, F. Andreotti, G.F. Watts, H. Ginsberg, P. Amarenco, A. Catapano, O.S. Descamps, E. Fisher, P.T. Kovanen, J.A. Kuivenhoven, P. Lesnik, L. Masana, Z. Reiner, M.R. Taskinen, L. Tokgözoglu, and A. Tybjærg-Hansen. 2010. European Atherosclerosis Society Consensus Panel. Lipoprotein(a) as a cardiovascular risk factor: current status. European Heart Journal 31: 2844–2853.PubMedCentralPubMedCrossRefGoogle Scholar
- 6.Morishita, R., J. Ishii, Y. Kusumi, S. Yamada, N. Komai, M. Ohishi, M. Nomura, H. Hishida, M. Niihashi, and M. Mitsumata. 2009. Association of serum oxidized lipoprotein(a) concentration with coronary artery disease: potential role of oxidized lipoprotein(a) in the vascular wall. Journal of Atherosclerosis and Thrombosis 16: 410–418.PubMedCrossRefGoogle Scholar
- 13.Safarova, M.S., M.V. Ezhov, O.I. Afanasieva, Y.G. Matchin, R.V. Atanesyan, I.Y. Adamova, E.A. Utkina, G.A. Konovalov, and S.N. Pokrovsky. 2013. Effect of specific lipoprotein(a) apheresis on coronary atherosclerosis regression assessed by quantitative coronary angiography. Atherosclerosis Supplements 14: 93–99.PubMedCrossRefGoogle Scholar
- 21.Alfthan, G., J. Pekkanen, M. Jauhiainen, J. Pitkäniemi, M. Karvonen, J. Tuomilehto, J.T. Salonen, and C. Ehnholm. 1994. Relation of serum homocysteine and lipoprotein(a) concentrations to atherosclerotic disease in a prospective Finnish population based study. Atherosclerosis 106: 9–19.PubMedCrossRefGoogle Scholar
- 26.Adams Jr., H.P., B.H. Bendixen, L.J. Kappelle, J. Biller, B.B. Love, D.L. Gordon, and E.E. Marsh 3rd. 1993. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. TOAST: Trial of Org 10172 in Acute Stroke Treatment. Stroke 24: 35–41.PubMedCrossRefGoogle Scholar
- 28.Matthews, K.A., M.F. Sowers, C.A. Derby, E. Stein, H. Miracle-McMahill, S.L. Crawford, and R.C. Pasternak. 2005. Ethnic differences in cardiovascular risk factor burden among middle-aged women: Study of Women's Health Across the Nation (SWAN). American Heart Journal 149: 1066–1073.PubMedCrossRefGoogle Scholar
- 42.Von Depka, M., U. Nowka-Göttl, R. Eisert, C. Dieterich, M. Barthels, I. Scharrer, A. Ganser, and S. Ehrenforth. 2000. Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism. Blood 96: 3364–3368.Google Scholar
- 45.Ohtahara, A., I. Hisatome, Y. Yamamoto, M. Furuse, K. Sonoyama, Y. Furuse, et al. 2001. The release of the substrate for xanthine oxidase in hypertensive patients was suppressed by angiotensin converting enzyme inhibitors and [alpha] 1-blockers. Journal of Hypertension 19: 575–582.PubMedCrossRefGoogle Scholar
- 46.Harpel PC, Chang VT, Borth W. Homocysteine and other sulfhydryl compounds enhance the binding of lipoprotein(a) to fibrin: a potential biochemical link between thrombosis, atherogenesis, and sulfhydryl compound metabolism. PNAS 1992:10193–10197.Google Scholar